High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand

Sriuranpong, Virote; Chantranuwat, Chavit; Huapai, N.; Chalermchai, Thep; Leungtaweeboon, K.; Lertsanguansinchai, Prasert; Voravud, Narin; Mutirangura, Apiwat

doi:10.1016/j.canlet.2005.08.029

Cited by 30 publications

(22 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The percentage of EGFR mutation reported in many studies correlate with that reported in our study (Lynch et al, 2004;Sriuranpong et al, 2006;Pirker et al, 2009;Sakuma et al, 2007).…”

Section: Number Ofpatientssupporting

confidence: 92%

“…Another factor that has a great influence on the EGFR mutation rate is the geographical origin of the analyzed patients. For quite some years it has been known that East Asian patients with NSCLC have a higher incidence of EGFR mutations, but, at the same, they show a lower incidence of KRAS mutations compared with other ethnic groups (Sriuranpong et al, 2006;Pirker et al, 2009;Sakuma et al, 2007).…”

Section: Number Ofpatientsmentioning

confidence: 99%

See 1 more Smart Citation

The frequency of epidermal growth factor receptor mutations in non-small-cell lung cancer patients from Egypt

Helmy¹,

Khalil²,

Ishak³

et al. 2015

Egyptian Journal of Pathology

View full text Add to dashboard Cite

Background Lung cancer with mutations in the epidermal growth factor receptor (EGFR) is one of the leading causes of cancer-related death, and non-small-cell lung cancer (NSCLC) has captured the attention of researchers. These mutations occur within EGFR exons 19, 18, 20, and 21.Objective Our study aimed at determining the prevalence of the mutation in the biopsy samples of NSCLC patients in Egypt.Patients and methods In this study, 195 adenocarcinoma (ACA) patients with NSCLC were diagnosed and graded on the basis of histopathology using hematoxylin and eosin stain. The samples were subjected to immunohistochemistry studies and were confirmed as positive using TTF1 and as negative using P63. The positive samples were subjected to PCR amplification for EGFR mutation study.Results On the basis of hematoxylin and eosin-stained sections, 15 of 195 ACA patients were of grade I, 160 patients (the majority) were of grade II, and 20 patients were of grade III (195 vs. 20, P < 0.001; 60 vs. 15, P < 0.001; 15 vs. 20, P < 0.37, statistically nonsignificant). Of the 195 ACA patients, 68 (34.8%) had tumor-associated EGFR mutations, 40 (58.8%) patients had deletion in codon 19, 16 (23.6%) patients had deletion of L858R in codon 21, six (8.8%) patients had insertion in codon 20, three (4.4%) patients had insertion in codon 18, and three (4.4%) patients had multiple mutations [40 vs.16, P < 0.001; 40 vs. 6, P < 0.001 (highly significant); 40 vs. 3, P < 0.001]. As regards sex, the incidence of EGFR mutations was higher in women (41, 60.3%) than in men (27, 39.7%) (68 vs. 41, P < 0.05; 68 vs. 27, P < 0.05; 41 vs. 27, P < 0.05). Tumors with an activating EGFR mutations were more likely to be from nonsmokers (43/63.3%) than from smokers (25/36.7%) (43 vs. 25, P < 0.001, significant). ConclusionThe current study has revealed that 34.8% of patients with NSCLC have tumor-associated EGFR mutations. Of which, 58.8% of the mutations were exon 19 deletions. EGFR mutations were more often found in tumors from female nonsmokers with ACA histopathology.

show abstract

“…The percentage of EGFR mutation reported in many studies correlate with that reported in our study (Lynch et al, 2004;Sriuranpong et al, 2006;Pirker et al, 2009;Sakuma et al, 2007).…”

Section: Number Ofpatientssupporting

confidence: 92%

Section: Number Ofpatientsmentioning

confidence: 99%

The frequency of epidermal growth factor receptor mutations in non-small-cell lung cancer patients from Egypt

Helmy¹,

Khalil²,

Ishak³

et al. 2015

Egyptian Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…EGFR is a transmembrane glycoprotein receptor with tyrosine kinase activity and is highly expressed in 45-70% of NSCLC patients (12,13). EGFR acts on the cell signal transduction pathway, promotes the differentiation and proliferation of tumor cells, promotes tumor angiogenesis and metastasis and inhibits apoptosis (14)(15)(16). Multiple studies have proven that customized therapy significantly improved the survival rate and life quality of EGFR-positive lung cancer patients (17,18).…”

Section: Discussionmentioning

confidence: 99%

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China

Abdurahman

Anwar

Turghun

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to investigate the mutation status of epidermal growth factor receptor (EGFR) and its association with clinical characteristics and tumor markers in non-small-cell lung cancer (NSCLC) patients from the Xinjiang Uygur Autonomous Region in China. We enrolled 51 cases of NSCLC patients who received radical surgical treatment in the First Affiliated Hospital of Xinjiang Medical University. Quantitative polymerase chain reaction was applied to detect exons 18, 19, 20 and 21 of the EGFR gene in tumor tissues. Multiple tumor markers, including carcinoembryonic antigen (CEA), were assessed preoperatively. The EGFR-positive rate was 49.02% (25/51), with a mutation rate of 8% (2/25) in exon 18, 52% (13/51) in exon 19, 40% (10/51) in exon 21 and no mutations in exon 20. The positive mutation rate in men and women was 37.5% (12/32) and 68.42%, respectively (13/19), with a statistically significantly higher rate in women (P<0.05). There were also statistically significant differences among adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma cases (P<0.05), while no statistically significant differences were observed in adenocarcinoma cases regarding degree of differentiation, lymph node metastasis and TNM stage (P>0.05). There was a statistically significant association between the EGFR gene mutation status and the preoperative serum CEA level (P<0.05). The mutation rate of the EGFR gene was 68.42% in female lung adenocarcinoma patients, which supports the application of targeted therapy in such cases. However, whether it is possible to obtain information regarding targeted therapy through measuring the level of serum CEA for NSCLC patients with unknown EGFR mutation status requires further investigation through related studies including a higher number of cases. IntroductionLung cancer is one of the most common malignant tumors in humans, with an equally high incidence in men and in women. Approximately 80% of lung cancer cases are non-small-cell lung cancer (NSCLC) (1). The majority of the patients present with advanced-stage lung cancer at diagnosis, when radical excision is no longer feasible (2) and the remaining treatment options include radiotherapy, chemotherapy and immune therapy. The rate of response to radiotherapy and chemotherapy is only 15-35%, which may not effectively improve the survival rate and life quality of the patients. Therefore, the total 5-year survival rate of lung cancer patients is only ~15% (2-4).Over the last few years, genetic testing and targeted therapy based on epidermal growth factor receptor (EGFR) gene mutation status has attracted significant attention. Multiple clinical studies indicated that tyrosine kinase inhibitors (TKIs) have effectively extended the survival time and improved the life quality of NSCLC patients (5), with a total effectiveness rate of >70%. However, the effectiveness rate of TKI treatment for wild-type EGFR cancers is only 10-15% (6). Therefore, it is crucial to determine the mutation status of the EGFR gene in NSC...

show abstract

“…An EGFR double-activating mutation involving an exon 19 deletion and L858R was first reported by Sriuranpong et al [8]. Subsequently, in a study involving 145 NSCLC patients, five cases of EGFR double-activating mutation were reported by Zhang et al [9].…”

Section: Discussionmentioning

confidence: 99%

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report

et al. 2011

View full text Add to dashboard Cite

IntroductionTo date, an epidermal growth factor receptor-activating mutation is recognized as a genetic hallmark that predicts a good response to treatment with epidermal growth factor receptor tyrosine kinase inhibitor. However, there has been less long-term observation of the mutational status within the same patient. To the best of our knowledge, this is the first case report which illustrates the instability of the genetic status of pulmonary adenocarcinoma cells.Case presentationA 64-year-old Japanese woman with advanced lung adenocarcinoma had been undergoing various anticancer treatments, including epidermal growth factor receptor tyrosine kinase inhibitor, for seven years. She had been receiving locoregional treatment in addition to systemic treatment. She maintained a good performance status until seven years after the initial diagnosis, although she had local and distant recurrences. We analyzed the genetic status of the epidermal growth factor receptor gene in a series of specimens obtained from various tumor-containing lesions throughout the therapeutic period. The results of the genetic analyses clearly showed that the spatial and temporal genetic heterogeneity of the epidermal growth factor receptor gene status originated from an identical tumor ancestor.ConclusionsAn alternative paradigm to determine a therapeutic strategy for a patient with lung cancer should be considered given the genetic heterogeneity and instability of tumor cells.

show abstract

High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand

Cited by 30 publications

References 19 publications

The frequency of epidermal growth factor receptor mutations in non-small-cell lung cancer patients from Egypt

The frequency of epidermal growth factor receptor mutations in non-small-cell lung cancer patients from Egypt

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China

Spatial and temporal genetic heterogeneity of epidermal growth factor receptor gene status in a patient with non-small cell lung cancer: a case report

Contact Info

Product

Resources

About